Home
Clinical Trials
NCT06793397

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Last Updated: 2025-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-10

Study Completion Date

2027-05-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder (MDD) Depression in Adults Depression - Major Depressive Disorder Depression Disorders Depression Disorder Depression

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

MDD Psychedelic Depression Major Depressive Disorder CYB003 CYB003-001 CYB003-002 Psilocybin psilocin-7438

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

Group Type EXPERIMENTAL

CYB003

Intervention Type DRUG

CYB003 is a deuterated psilocin analog.

Psychological Support

Intervention Type BEHAVIORAL

Manualized psychological support performed by facilitator.

Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

Group Type EXPERIMENTAL

CYB003

Intervention Type DRUG

CYB003 is a deuterated psilocin analog.

Psychological Support

Intervention Type BEHAVIORAL

Manualized psychological support performed by facilitator.

Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Group Type PLACEBO_COMPARATOR

Psychological Support

Intervention Type BEHAVIORAL

Manualized psychological support performed by facilitator.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CYB003

CYB003 is a deuterated psilocin analog.

Intervention Type DRUG

Psychological Support

Manualized psychological support performed by facilitator.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must meet all the following criteria to be included in the trial:
* Age18 to 85 years.
* Participant has a diagnosis of MDD.
* Moderate to severe depression at Screening.
* Participants have been on a stable dose of antidepressant medication at an adequate dose in the last 4 weeks prior to Screening.
* Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
* Participants with well controlled hypertension.
* Participant is able to refrain from smoking during the dosing session.
* Participants must use a condom plus spermicide during the trial and for 12 weeks afterwards.

Participants of childbearing potential must agree to use a highly effective method of and a negative pregnancy test at Screening and Day -1 prior to dosing.

* Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
* Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

* Participants with any of the following characteristics/conditions will be excluded from trial participation:
* Current or previously diagnosed schizophrenia spectrum or other psychotic disorders.
* Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
* Significant suicide risk within 12 months of Screening.
* Current or previous diagnosis of treatment-resistant MDD.
* Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
* Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer.
* Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder).
* Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
* Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
* Participants have a presence or relevant history of organic brain disorders.
* Participant is taking or has taken OTC doses of 5 hydroxytryptophan or St John's Wort within prior to trial medication administration.
* Strenuous exercise prior to each clinic visit.
* Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
* Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
* Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
* History of serotonin syndrome.
* Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Felix Mazer

Role: STUDY_DIRECTOR

Cybin IRL Limited

Locations

Explore where the study is taking place and check the recruitment status at each participating site.